Correspondence 0001493152-24-008471 from Bone Biologics Corp (BBLG)

Bone Biologics Corp
Date: March 1, 2024 · CIK: 0001419554 · Accession: 0001493152-24-008471

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-276771

Date

March 1, 2024

Author

President

Form

CORRESP

Company

Bone Biologics Corp

Letter

Bone Biologics Corporation

Burlington Woods Drive, Suite 100

Burlington, MA 01803

March 1, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Attn: Jane Park

Re: Bone Biologics Corporation

Registration Statement on Form S-1

File No. 333-276771

Ladies and Gentlemen:

On February 29, 2024, Bone Biologics Corporation (the “Company”) requested acceleration of the effective date of the above-referenced Registration Statement so that it would become effective at 1:00 p.m. Eastern Time on March 1, 2024 or as soon thereafter as practicable. The Company hereby withdraws that request and respectfully requests, in accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced Registration Statement on March 4, 2024 at 9:00 a.m. Eastern Time or as soon thereafter as practicable.

If you have any questions regarding this request, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.

Very
truly yours,
Bone
Biologics Corporation

Show Raw Text

CORRESP
1
filename1.htm

Bone
Biologics Corporation

2
Burlington Woods Drive, Suite 100

Burlington,
MA 01803

March
1, 2024

VIA
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

Attn:
Jane Park

    Re:
    Bone
                                            Biologics Corporation

    Registration
    Statement on Form S-1

    File
    No. 333-276771

Ladies
and Gentlemen:

On
February 29, 2024, Bone Biologics Corporation (the “Company”) requested acceleration of the effective date of the above-referenced
Registration Statement so that it would become effective at 1:00 p.m. Eastern Time on March 1, 2024 or as soon thereafter as practicable.
The Company hereby withdraws that request and respectfully requests, in accordance with Rule 461 promulgated under the Securities Act
of 1933, as amended, the effectiveness of the above-referenced Registration Statement on March 4, 2024 at 9:00 a.m. Eastern Time or as
soon thereafter as practicable.

If
you have any questions regarding this request, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.

    Very
    truly yours,

    Bone
    Biologics Corporation

    By:
    /s/
    Jeffrey Frelick

    Jeffrey
    Frelick

    President
    and Chief Executive Officer

SecProbe.io